News - Page 2 of 2 - iM4TB

Professor Stewart Cole appointed President of the Institut Pasteur

On October 13, 2017, Professor Stewart Cole was appointed President of the Institut Pasteur by its Board of Directors for a four-year term. He will take office in January 2018.

Read more here            

iM4TB awarded USD 2.45 m for anti-TB drug clinical trials

The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB USD 2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.

Read more here

Suvorov Prize 2015

NEARMEDIC Plus wins the silver medal of the Suvorov Prize 2015.

Nobel Laureate Françoise Barré-Sinoussi as Patron of iM4TB

The Innovative Medicines for Tuberculosis (iM4TB) Foundation announces Nobel Laureate Françoise Barré-Sinoussi as Patron

French virologist Professor Barré-Sinoussi has worked at the Institut Pasteur in Paris since 1971 and co-discovered the human immunodeficiency virus (HIV), the causative agent of AIDS in 1983. In 2008, she and Professor Luc Montagnier were awarded the Nobel Prize in Medicine or Physiology for their discovery. Amongst her other distinctions, Prof. Barré-Sinoussi is a Grand Officer of the French Legion of Honour. She received an Honorary doctorate from EPFL in 2014.

Read More

EPFL tuberculosis non-profit foundation iM4TB receives major grant

EPFL spin-off “Innovative Medicines for Tuberculosis” (iM4TB) has been awarded nearly USD 750,000 by the Bill & Melinda Gates Foundation to develop a breakthrough drug against tuberculosis.

Read more here

Prof. Stewart Cole elected to French National Academy of Pharmacy

Professor Stewart Cole has been formally elected into the National Academy of Pharmacy in France as an Associate Member. Created in 1803, the French National Academy of Pharmacy began life as the “Paris Pharmacy Company”, which was officially recognized as a charity in 1877. The organization grew into the “Academy of Pharmacy” in 1946, and took its final form in 1979.

Read more here

EPFL-Nearmedic collaboration

The pharmaceutical company Nearmedic is collaborating with EPFL to participate in the development of a treatment against tuberculosis. The company bought a license covering the use of the molecule in most countries of the former Soviet Union, where multi-resistant strains are prevalent.

Read more here